Streetwise Reports' Article Archives — October 2023 back to current month (7)
Biotech to Advance New Type 1 Diabetes Drug Into Clinic (10/23/2023)
Dosing of the first patient is expected in Q4/23 in this Phase 1 trial to be done in Australia, noted an H.C. Wainwright & Co. report.
Approval Likely in U.S., EU for New Drug for Prader-Willi (10/12/2023)
Despite recent positive clinical trials, the biopharma behind this treatment remains undervalued presenting a buying opportunity, noted an Oppenheimer report.
Drug Reform Streaming Co. Starts Trading on CSE (10/12/2023)
This company investing in and incubating companies at the forefront of drug policy reform has started trading on the Canadian Securities Exchange. One writer says buying stock is a chance to be a part of a "movement."
Diagnostics Biotech Beats Revenue Estimates in Q3/23 (10/11/2023)
The Belgium-based company is well on its way to achieving, and possibly exceeding, full-year revenue guidance, noted an Oppenheimer report.
Chen Still Likes This Precious Metal in Q4 (10/09/2023)
If you've been following asset manager Chen Lin's quarterly picks on Streetwise Reports, you know he is bullish on one particular precious metal, and the fourth quarter of 2023 is no exception.
Trial of New Drug for Acute Leukemia Meets Primary Endpoint (10/05/2023)
The biopharma behind it plans to submit a new drug application, seeking approval of the compound, by year-end, noted an H.C. Wainwright & Co. report.
New CAR-T Therapy Shows Potency in Certain Patients (10/04/2023)
Study results for patients with relapsed/refractory multiple myeloma continue to be "favorable," noted a ROTH Capital Partners report.
More Archives
2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
